Associate professor, Karolinska Institutet, KI-Alzheimer Disease Research Center, KASPAC, Novum, Floor 5, SE-141-57, Huddinge, Sweden.
Expert Rev Pharmacoecon Outcomes Res. 2007 Feb;7(1):83-90. doi: 10.1586/14737167.7.1.83.
Care of dementia is extremely resource demanding and has a great impact on both the formal care systems and the situation for informal carers. Thus, the question of cost-effectiveness is crucial. This presentation is, to a great extent, based on the dementia project by the Swedish council on technology assessment in health care. After the database search and quality judgment of papers, 22 papers of drug treatment were finally included. A summary of the situation as regards cost-effectiveness on drugs for Alzheimer's disease showed that no evidence could be stated on empirical studies. Although most modeling studies indicate cost-effectiveness, this was not regarded as enough support for cost-effectiveness since the empirical studies were inconclusive. The need for larger empirical studies of high standards of quality and modeling studies including an enlarged sensitivity analysis, is evident.
痴呆症的护理需要大量资源，对正规护理系统和非正规护理人员的状况都有重大影响。因此，成本效益问题至关重要。本演讲在很大程度上基于瑞典医疗保健技术评估委员会的痴呆症项目。在对论文进行数据库搜索和质量评估后，最终纳入了 22 篇药物治疗论文。关于阿尔茨海默病药物的成本效益情况总结表明，实证研究无法提供证据。虽然大多数模型研究表明具有成本效益，但由于实证研究尚无定论，这并不能充分证明成本效益。显然，需要开展更多高质量的实证研究和模型研究，并进行扩大敏感性分析。
